

CADTH RAPID RESPONSE REPORT: SUMMARY OF ABSTRACTS

Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines

Service Line:	Rapid Response Service
Version:	1.0
Publication Date:	August 28, 2018
Report Length:	10 Pages

Authors: Michelle Clark, Suzanne McCormack

Cite As: *Post-Partum Screening and Monitoring for Gestational Diabetes: Clinical Effectiveness and Guidelines*. Ottawa: CADTH; 2018 Aug. (CADTH rapid response report: summary of abstracts).

Acknowledgments:

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Research Questions

1. What is the clinical effectiveness of an intervention to screen and monitor patients post-partum gestational diabetes?
2. What are the evidence-based guidelines regarding post-partum gestational diabetes screening or monitoring?

Key Findings

Three systematic reviews, two randomized controlled trials, six non-randomized studies, and four evidence-based guidelines were identified regarding the screening and monitoring of post-partum gestational diabetes.

Methods

A limited literature search was conducted on key resources including PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit retrieval to study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2013 and August 15, 2018. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	Post-partum patients with gestational diabetes
Intervention	Compliance tools (e.g., text message, e-mail, mail reminder)
Comparators	Q1: Alternative comparators Q2: No comparator
Outcomes	Q1: Reducing harm, increasing compliance Q2: Guidelines
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based guidelines

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

Three systematic reviews, two randomized controlled trials, six non-randomized studies, and four evidence-based guidelines were identified regarding the screening and monitoring of post-partum gestational diabetes. No relevant health technology assessments were identified.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

Three systematic reviews,¹⁻³ two randomized controlled trials,⁴⁻⁵ six non-randomized studies,⁶⁻¹¹ were identified regarding the screening and monitoring of post-partum gestational diabetes. Generally, the results of these studies showed no or little difference between groups in terms of postnatal testing follow through. Details regarding the studies are provided in Table 2.

Four evidence-based guidelines¹²⁻¹⁵ were identified regarding the post-partum management of gestational diabetes. The guidelines recommend that women with gestational diabetes be encouraged to breastfeed.^{12,14} A fasting glucose test should be offered between six weeks¹²⁻¹⁵ to six months^{12,14} post-partum. An annual HbA1c test should be offered to women who had gestational diabetes but who test negative at their postnatal test.¹⁵ Lifestyle advice, including weight control, diet, and exercise, should be provided postnatally.^{12-13,15}

Table 2: Summary of Included Studies

Author, Year	Population, Setting, and Study Characteristics	Intervention	Comparators	Results and Authors' Conclusions
Systematic Reviews				
Jeppesen, 2015 ¹	Women with previous GDM Primary and secondary healthcare facilities 6 studies	Reminder and reminder systems for post-partum screening for type 2 diabetes: <ul style="list-style-type: none"> • Letters • Emails • Personal telephone calls 	Not specified	<ul style="list-style-type: none"> • The efficacy of reminders varied between studies • Two studies found that phone calls were good reminders • Reminding women or healthcare providers separately was more effective than reminding them together
Middleton, 2015 ²	Women with previous GDM One RCT	Any type of reminder	Control groups (not further specified)	<ul style="list-style-type: none"> • One low quality study was identified comparing mailed reminders with no reminder 3 months

Author, Year	Population, Setting, and Study Characteristics	Intervention	Comparators	Results and Authors' Conclusions
				after giving birth <ul style="list-style-type: none"> Uptake of oral glucose tolerance tests was higher in groups who received a reminder
Carson, 2013 ³	Women with previous GDM 54 studies	Proactive patient contact programs: <ul style="list-style-type: none"> Phone calls Education programs Postal reminders 	No reminder	The use of a reminder system increased post-partum testing between 33% and 60%
Randomized Controlled Trials				
Khorshidi Roozbahani, 2015 ⁴	Women with previous GDM (N = 80)	Telephone follow-up on blood glucose levels during pregnancy and post-partum screening <ul style="list-style-type: none"> Calls for 10 weeks during pregnancy and one call 6 weeks post-partum 	Telephone follow-up 3 times during pregnancy and one call 6 weeks post-partum	The rate of post-partum glucose screening was statistically significantly higher in the intervention group
Van Ryswyk, 2015 ⁵	Women with previous GDM (N = 276)	Text message reminder system (n = 140): <ul style="list-style-type: none"> Sent a reminder text at 6 weeks post-partum to attend OGTT Additional reminder texts sent at 3 months and 6 months if required 	Text message reminder system (n = 136): <ul style="list-style-type: none"> Sent a reminder text 6 months post-partum to attend OGTT 	<ul style="list-style-type: none"> Attendance for OGTT was not significantly different between groups within 6 months post-partum Although there was no difference between groups, the authors noted a high rate of test completion in both groups
Non-Randomized Studies				
Benhalima, 2017 ⁶	Women with previous GDM (N = 7269 registered)	GDM recall register <ul style="list-style-type: none"> Registrants receive a yearly reminder to have a fasting plasma glucose test 	No comparator	<ul style="list-style-type: none"> Yearly response rates varied from 74.4% after the first year to 61.8% after the fifth year Women who never responded were more often less than 30 years of age and were more often obese
Soffer, 2017 ⁷	Women with previous GDM (n = 107 pre-intervention and n = 42 post-intervention)	Advanced order sets for: <ul style="list-style-type: none"> Glucose monitoring at 35-week pregnancy visit Educational module Nutritionist phone call reminders for post- 	Before and after comparison	<ul style="list-style-type: none"> The percentage of orders placed for post-partum glucose testing was higher after the intervention was implemented There was no increased observed in

Author, Year	Population, Setting, and Study Characteristics	Intervention	Comparators	Results and Authors' Conclusions
		partum glucose testing		attendance of the 6-week post-partum appointment
Carral, 2015 ⁸	Pregnant women with diabetes (including gestational, type 1 and type 2) (N = 104) Prospective, single-center, interventional study	Telemedicine group monitored with follow-up by the Gestational Diabetes Unit and web-based telemedicine	Control group monitored by follow-up by the Gestational Diabetes Unit alone	<ul style="list-style-type: none"> There were no significant differences observed in mean glycated hemoglobin level during or after pregnancy between groups
Carson, 2015 ⁹	Pregnant women with GDM (N = 40) Prospective cohort study	Blood drawn in the office for random sugar and HbA1c at the post-partum visit	OGTT testing at an outside laboratory separate from the post-partum visit	<ul style="list-style-type: none"> All of the women who were eligible had their blood drawn in the office while only 53% in the OGTT group completed testing
Mendez-Figuerosa, 2014 ¹⁰	Women with previous GDM	1-year intensive follow-up program with nurse and outreach worker case management	Women with GDM attending the same clinic before the intervention was implemented	<ul style="list-style-type: none"> Adherence to post-partum OGTT increased from 43.1% to 59.4% after implementing the program The authors predicted the change would have resulted in the detection of an additional 12 cases of diabetes or pre-diabetes the previous year
Carson, 2013 ¹¹	Women with GDM (N = 69)	Fingerstick blood glucose 4 times a day for 2 days at 6 weeks post-partum followed by an OGTT	No comparator group	<ul style="list-style-type: none"> 18% of women participating in the study completed both the fingerstick and OGTT 30% of participants completed at least part of the testing The authors determined that the home testing option did not improve participation rates

GDM = gestational diabetes mellitus; OGTT = oral glucose tolerance test; RCT = randomized controlled trial.

References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

1. Jeppesen C, Kristensen JK, Ovesen P, Maindal HT. The forgotten risk? A systematic review of the effect of reminder systems for postpartum screening for type 2 diabetes in women with previous gestational diabetes. *BMC Res Notes*. 2015 Aug 26;8:373.
[PubMed: PM26306499](#)
2. Middleton P, Crowther CA. Reminder systems for women with previous gestational diabetes mellitus to increase uptake of testing for type 2 diabetes or impaired glucose tolerance. *Cochrane Database Syst Rev*. 2014 Mar 18(3):CD009578.
[PubMed: PM24638998](#)
3. Carson MP, Frank MI, Keely E. Original research: postpartum testing rates among women with a history of gestational diabetes--systematic review. *Prim Care Diabetes*. 2013 Oct;7(3):177-186.
[PubMed: PM23684416](#)

Randomized Controlled Trials

4. Khorshidi Roozbahani R, Geranmayeh M, Hantoushzadeh S, Mehran A. Effects of telephone follow-up on blood glucose levels and postpartum screening in mothers with gestational diabetes mellitus. *Med J Islam Repub Iran*. 2015;29:249.
[PubMed: PM26793640](#)
5. Van Ryswyk EM, Middleton PF, Hague WM, Crowther CA. Postpartum SMS reminders to women who have experienced gestational diabetes to test for Type 2 diabetes: the DIAMIND randomized trial. *Diabet Med*. 2015 Oct;32(10):1368-1376.
[PubMed: PM25816702](#)

Non-Randomized Studies

6. Benhalima K, Verstraete S, Muylle F, et al. Implementing a reminder system in the northern part of Belgium to stimulate postpartum screening for glucose intolerance in women with gestational diabetes: the "sweet pregnancy" project. *Int J Endocrinol*. 2017;2017:3971914.
[PubMed: PM28775742](#)
7. Soffer MD, Factor SH, Rosenman A, Levy C, Stone J. Improving postpartum glucose monitoring in women with gestational diabetes. *J Matern Fetal Neonatal Med*. 2017 Dec;30(24):3014-3019.
[PubMed: PM27936990](#)

8. Carral F, Ayala Mdel C, Fernandez JJ, et al. Web-based telemedicine system is useful for monitoring glucose control in pregnant women with diabetes. *Diabetes Technol Ther.* 2015 May;17(5):349-354.
[PubMed: PM25629547](#)
9. Carson MP, Morgan B, Gussman D, Brown M, Rothenberg K, Wisner TA. SUGAR: spotting undiagnosed glucose abnormal results--a new protocol to increase postpartum testing among women with gestational diabetes mellitus. *Am J Perinatol.* 2015 Feb;32(3):299-306.
[PubMed: PM25093913](#)
10. Mendez-Figueroa H, Daley J, Breault P, et al. Impact of an intensive follow-up program on the postpartum glucose tolerance testing rate. *Arch Gynecol Obstet.* 2014 Jun;289(6):1177-1183.
[PubMed: PM24481876](#)
11. Carson MP, Lewis BG, Pagan ER, Evers M. Evaluation of home testing to improve follow up after gestational diabetes (Fingerstick Assessments of Sugar Two-months postpartum or FAST). *Obstet Med.* 2013 Sep;6(3):120-124.
[PubMed: PM27708703](#)

Guidelines and Recommendations

12. Feig DS, Berge H, Donovan L, et al. Diabetes and pregnancy. *Can J Diabetes.* 2018;42 Suppl 1:S255-S282.
[https://www.canadianjournalofdiabetes.com/article/S1499-2671\(17\)30849-3/pdf](https://www.canadianjournalofdiabetes.com/article/S1499-2671(17)30849-3/pdf). Accessed 2018 Aug 28.
13. Management of diabetes: a national clinical guideline (*SIGN publication no. 116*). Edinburgh (GB): Scottish Intercollegiate Guidelines Network (SIGN); 2010, updated 2017: <https://www.sign.ac.uk/assets/sign116.pdf>. Accessed 2018 Aug 28.
See: 7.11 Postnatal Care, page 67
7.12 Follow up of Women with GDM, page 68
14. Berger H, Gagnon R, Sermer M, et al. Diabetes in pregnancy. *J Obstet Gynaecol Can.* 2016;38(7):667-679.e661.
[PubMed: PM27591352](#)
See: Recommendation 11, page 669
15. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. (*NICE guideline NG3*) 2015; <https://www.nice.org.uk/guidance/ng3>. Accessed 2018 Aug 28.
See: Postnatal Care, page 11

Appendix — Further Information

Systematic Reviews and Meta-Analyses– Alternative Outcomes

16. Nielsen KK, Kapur A, Damm P, de Courten M, Bygbjerg IC. From screening to postpartum follow-up - the determinants and barriers for gestational diabetes mellitus (GDM) services, a systematic review. *BMC Pregnancy Childbirth*. 2014 Jan 22;14:41. [PubMed: PM24450389](#)

Non-Randomized Studies – No Abstract Available

17. Halperin IJ, Sehgal P, Lowe J, Hladunewich M, Wong BM. Increasing timely postpartum oral glucose tolerance test completion in women with gestational diabetes: a quality-improvement initiative. *Can J Diabetes*. 2015 Dec;39(6):451-456. [PubMed: PM26277221](#)

Qualitative Studies

18. Kilgour C, Bogossian FE, Callaway L, Gallois C. Postnatal gestational diabetes mellitus follow-up: perspectives of Australian hospital clinicians and general practitioners. *Women Birth*. 2018 May 4. [Epub ahead of print] [PubMed: PM29735392](#)
19. Pennington AVR, O'Reilly SL, Young D, Dunbar JA. Improving follow-up care for women with a history of gestational diabetes: perspectives of GPs and patients. *Aust J Prim Health*. 2017 Apr;23(1):66-74. [PubMed: PM28442034](#)
20. Rafii F, Rahimparvar SFV, Mehrdad N, Keramat A. Barriers to postpartum screening for type 2 diabetes: a qualitative study of women with previous gestational diabetes. *Pan Afr Med J*. 2017;26:54. [PubMed: PM28451031](#)
21. Koning SH, Lutgers HL, Hoogenberg K, Trompert CA, van den Berg PP, Wolffenbuttel BH. Postpartum glucose follow-up and lifestyle management after gestational diabetes mellitus: general practitioner and patient perspectives. *J Diabetes Metab Disord*. 2016;15:56. [PubMed: PM27981042](#)
22. Van Ryswyk EM, Middleton PF, Hague WM, Crowther CA. Women's views on postpartum testing for type 2 diabetes after gestational diabetes: six month follow-up to the DIAMIND randomised controlled trial. *Prim Care Diabetes*. 2016 Apr;10(2):91-102. [PubMed: PM26320407](#)
23. Kilgour C, Bogossian FE, Callaway L, Gallois C. Postnatal gestational diabetes mellitus follow-up: Australian women's experiences. *Women Birth*. 2015 Dec;28(4):285-292. [PubMed: PM26197766](#)

24. Nielsen JH, Olesen CR, Kristiansen TM, Bak CK, Overgaard C. Reasons for women's non-participation in follow-up screening after gestational diabetes. *Women Birth*. 2015 Dec;28(4):e157-163.
[PubMed: PM25997731](#)
25. Paez KA, Eggleston EM, Griffey SJ, et al. Understanding why some women with a history of gestational diabetes do not get tested for diabetes. *Womens Health Issues*. 2014 Jul-Aug;24(4):e373-379.
[PubMed: PM24981396](#)

Clinical Practice Guidelines – Methodology Not Specified

26. Queensland Clinical Guidelines. Gestational diabetes mellitus. Brisbane (AU): The State of Queensland (Queensland Health); 2015:
https://www.health.qld.gov.au/_data/assets/pdf_file/0023/140099/g-gdm.pdf. Accessed 2018 Aug 28.

Review Articles

27. Carson MP, Ananth CV, Gyamfi-Bannerman C, Smulian J, Wapner RJ. Postpartum testing to detect persistent dysglycemia in women with gestational diabetes mellitus. *Obstet Gynecol*. 2018 Jul;132(1):193-198.
[PubMed: PM29889746](#)
28. Poola-Kella S, Steinman RA, Mesmar B, Malek R. Gestational diabetes mellitus: postpartum risk and follow up. *Rev Recent Clin Trials*. 2018 Jan 31;13(1):5-14.
[PubMed: PM28901851](#)
29. Hamel MS, Werner EF. Interventions to improve rate of diabetes testing postpartum in women with gestational diabetes mellitus. *Curr Diab Rep*. 2017 Feb;17(2):7.
[PubMed: PM28150160](#)
30. Martinez NG, Niznik CM, Yee LM. Optimizing postpartum care for the patient with gestational diabetes mellitus. *Am J Obstet Gynecol*. 2017 Sep;217(3):314-321.
[PubMed: PM28455081](#)